MedTrace Logo

Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy

NCT07222280 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-10-29

No results posted yet for this study

Summary

The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease.

* Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting?
* Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio

Conditions

  • Alzheimer Dementia
  • Alzheimer Disease
  • Delirium Confusional State
  • Encephalopathy
  • Cognitive Abnormality

Interventions

DIAGNOSTIC_TEST

Quest AD-Detect blood test

Blood will be collected and sent for testing using the Quest AD-Detect blood test

Sponsors & Collaborators

  • Covenant Health, US

    lead OTHER

Principal Investigators

  • Samuel Moore, MD · Covenant Health, Canada

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-10
Primary Completion
2026-03-31
Completion
2026-03-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07222280 on ClinicalTrials.gov